Insiders Trades
TB
TRex Bio, Inc. Stock: price and insider trades · United States
2 insiders bought €3.4M of shares over the last 90 days, the latest filed 15 Oct 2026.
Cluster: 2 buyers in 30 daysTRex Bio, Inc.: what insiders have been doing
TRex Bio, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for TRex Bio, Inc. logged 10 filings by 3 insiders.
The flow runs one way only: 2 insiders bought (3 purchases totalling €3.4M) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €2.2M from Alexandria Venture Investments, LLC, disclosed on 15 October 2026, or 0.67% of market capitalisation. Those buying include 2 major shareholders.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 15 October 2026, 3 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 10 filings here. The full history, which starts in 2026, counts 3 purchases against no sales.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
10
Thresholds
n/a
Buy Volume
€3M
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleSVLSF VI, LLC2 buys
Alexandria Venture Investments, LLC1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
US$13.60
Analyst consensus
Income statement
EBITDA-US$49.4M
Balance sheet & cash
Market capUS$373.3M
Debt / Equity0%
Profitability & ownership
% insiders1.1%
% institutions0.0%
Last declaration on 15 October 2026
Declarations10 total
1,167,930 sharesCommon StockSEC:0001722024-26-000004:0
178,571 shares@ US$14.00Common StockSEC:0001722024-26-000004:1
Canonical exit: 11 Jan 2027 (T+90)
1,574,074 shares0Common StockSEC:0001829126-26-011084:1
3,074 shares@ US$14.003.3% of flowCommon StockSEC:0001829126-26-011084:3
Canonical exit: 6 Jan 2027 (T+90)
41,871 sharesCommon StockSEC:0001193125-26-420734:0
475,411 shares0Common StockSEC:0001829126-26-011084:2
89,783 shares@ US$14.0096.7% of flowCommon StockSEC:0001829126-26-011084:0
Canonical exit: 6 Jan 2027 (T+90)
53,892 shares0Common StockSEC:0001829126-26-011084:4
16,277 shares0Common StockSEC:0001829126-26-011084:5
669,939 shares0Common StockSEC:0001829126-26-011084:6
10 of 10 declarations
About TRex Bio, Inc.
TRex Bio, Inc. is a biotechnology company focused on developing innovative solutions for disease treatment. It is listed on the NASDAQ under the ticker TRBX.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
